The future of rapid and enduring neuropsychiatric treatments: From psychedelics to non-hallucinatory psychoplastogens

Serotonin molecule [Vladimir/Adobe Stock]

Neuropsychiatric disorders, such as depression and anxiety, are among the leading causes of disability worldwide. Almost one billion people globally — roughly one out of eight individuals — live with a mental disorder, with anxiety and depressive disorders the most common, according to the World Health Organization. Yet current therapies such as selective serotonin reuptake inhibitors (SSRIs) offer limited efficacy and come with undesirable side effects. Additionally, they may take weeks to produce noticeable benefits.

These challenges have sparked interest in alternative treatments, including psychedelics and psychoplastogens, for mental health treatment, as noted by Dr. Kurt Rasmussen, Delix‘s chief scientific officer. “There are now a lot of researchers looking at psychoplastogens as a way to help remodel those circuits and treat depression and anxiety mor…

Read more
  • 0